1281P - Relevance between PD-L1 and radiological invasiveness in pathological stage I lung adenocarcinoma

Date 09 September 2017
Event ESMO 2017 Congress
Session Poster display session
Topics Cancer in Adolescents
Non-Small-Cell Lung Cancer, Early Stage
Lung and other Thoracic Tumours
Presenter Gouji Toyokawa
Citation Annals of Oncology (2017) 28 (suppl_5): v453-v456. 10.1093/annonc/mdx381
Authors G. Toyokawa, K. Takada, T. Okamoto, Y. Kozuma, T. Matsubara, S. Takamori, T. Akamine, M. Katsura, F. Shoji, Y. Maehara
  • Department Of Surgery And Science, Graduate School of Medical Sciences, Kyushu University, 812-8582 - Fukuoka/JP

Abstract

Background

Programmed death-ligand 1 (PD-L1) was reported to predict the response of immunotherapy; however, the association between PD-L1 expression and radiological/pathological features has yet to be elucidated.

Methods

A total of 292 patients with resected pathological stage I adenocarcinoma were analyzed for PD-L1 expression by immunohistochemistry and evaluated to determine the association between PD-L1 expression and the radiological/pathological invasiveness. Specifically, the radiological invasiveness and noninvasiveness were determined based on the consolidation/tumor (C/T) ratio, with a cut-off value of 0.25 by thin-section computed tomography.

Results

Among 292 patients, 47 (16.1%) were positive for PD-L1 expression; the remaining 245 patients (83.9%) were negative for PD-L1 expression. Fisher’s exact test demonstrated that PD-L1 expression was significantly associated with a higher C/T ratio (P=0.029) and higher maximum standardized uptake value (SUVmax; P=0.004). The mean values of C/T ratio and SUVmax in patients with and without PD-L1 expression were 0.845±0.052 and 7.241±0.795, and 0.607±0.023 and 3.60±0.364, respectively (P

Conclusions

PD-L1 expression was significantly associated with radiological/pathological invasive adenocarcinomas. This study provides the first evidence of the radiological/pathological invasiveness in resected pathological stage I adenocarcinoma with PD-L1 expression.

Clinical trial identification

Legal entity responsible for the study

Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

Funding

None

Disclosure

All authors have declared no conflicts of interest.